Clinical Trial Search

Primary: Six Month Survival Rate — 25; 67; 33 percentage of patients

Primary: Complete Response — 27.78 percentage of patients

Primary: Percent Heavy Drinking Days — 0.63; 0.14; 0.09; 0.17 percentage of days

Primary: Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community…

Primary: The Number of Subjects Who Reported Treatment-emergent Adverse Events (AE's) — 60; 59 participants

Primary: Number of Participants With One or More Drug-Related Adverse Events (AEs) or Any Serious AEs During the Single-Dose (SD) Period — 0; 0; 0; 0 participants

Primary: Percentage of Participants With Objective Response (OR) — 34.6 percentage of participants

Primary: Change From Baseline in Worst Pain in the Past 24 Hours Assessed by Brief Pain Inventory (BPI) Short Form Questionnaire Score at Day 29 — 6.7; 6.9; -1.8; -1.8 Units on a…

Primary: Change in Mean Daily Pain Score From Baseline to Week 3 (With LOCF) — -0.94; -0.97 units on a scale

Primary: Change From Baseline in Ocular Surface Disease Index© (OSDI) Score — 36.83; 38.51; 38.86; -14.72 Score on a scale

Primary: Knee Stability — 29; 26; 12; 17 participants

Primary: Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline — 2; 3 participants

Primary: Safety, as Defined by the Occurence of Serious Adverse Events (SAE's), of FCM Compared to SMC — 17; 11 participants

Primary: Pathologic Complete Response Rate — 10.4; 20.8 percentage of participants

Primary: Part A: Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametnib — 509; 524; 259; 255 Nanograms per…